Point: Active surveillance for favorable risk prostate cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 7, 2007, Pages 693-698

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Doubling time; Prostate cancer surveillance; PSA kinetics; Watchful waiting

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; COMORBIDITY; DISEASE COURSE; HUMAN; PATIENT SELECTION; PROSTATE CANCER; REVIEW;

EID: 34547960967     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0060     Document Type: Review

References (25)

1. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 2005;97:1132-1137.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
3. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial tadiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
4. Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-385.
5. Albertsen P, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-2101.
6. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancel and the Will Rogers phenomenon. J Natl Cancer Inst 2005;97: 1248-1253.
7. Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate cancer. Relationship of tumor volume to clinical significance fot treatment of prostate cancer. Cancer 1993;71:933-938.
8. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
9. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-3593.
10. Irwin MB, Trapasso JG. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 1994;44:862-867; discussion 867-868.
11. Cupp MR, Bostwick DG, Myers RP, Oestetling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995;153:1543-1548.
12. Goto Y, Ohori M, Arakawa A, et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996;156:1059-1063.
13. Epstein JI, Carmichael M, Partin AW, et al. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993;149:1478-1481.
14. Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage Tic prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160: 2407-2411.
15. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001;166:104-109.
16. Augustin H, Hammerer PG, Graefen M, et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 2003;43:455-460.
17. Anast JW, Andriole GL, Bismar TA, et al. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004;64:544-550.
18. Choo R, DeBoer G, Klotz L. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001;50:615-620.
19. Kakehi Y. PSA DT in Japanese active surveillance cohort (48 patients). Jpn J Clin Oncol 2003;33:1-5.
20. Egawa S, Arai Y, Tobisu K, et al. Use of pretreatment prostatespecific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 2000;3:269-274.
21. McLaren DB, McKenzie M, Duncan G, et al. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998;82:342-348.
22. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-135.
23. Choo R, Klotz L, Danjoux C, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167:1664-1669.
24. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165-8169.
25. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-1984.